US 12,005,146 B2
Methods of treatment using cholestosome vesicles for incorporation of molecules into chylomicrons
Jerome J. Schentag, Amherst, NY (US); Mary P. McCourt, Amherst, NY (US); Lawrence Mielnicki, Buffalo, NY (US); and Julie Hughes, Williamsville, NY (US)
Assigned to THERASYN SENSORS, INC., Eggertsville, NY (US)
Filed by THERASYN SENSORS, INC, Eggertsville, NY (US)
Filed on Mar. 24, 2023, as Appl. No. 18/126,251.
Application 18/126,251 is a division of application No. 17/337,283, filed on Jun. 2, 2021, granted, now 11,633,364.
Application 17/337,283 is a division of application No. 16/527,579, filed on Jul. 31, 2019, granted, now 11,052,052, issued on Jul. 6, 2021.
Application 16/527,579 is a continuation of application No. 15/603,992, filed on May 24, 2017, granted, now 10,369,114, issued on Aug. 6, 2019.
Application 15/603,992 is a continuation of application No. 14/776,308, granted, now 9,693,968, issued on Jul. 4, 2017, previously published as PCT/US2014/027761, filed on Mar. 14, 2014.
Claims priority of provisional application 61/783,003, filed on Mar. 14, 2013.
Prior Publication US 2023/0277471 A1, Sep. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/51 (2006.01); A61K 9/127 (2006.01); A61K 31/12 (2006.01); A61K 31/137 (2006.01); A61K 31/19 (2006.01); A61K 31/546 (2006.01); A61K 31/7034 (2006.01); A61K 31/713 (2006.01); A61K 38/14 (2006.01); A61K 38/28 (2006.01); A61K 39/29 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01)
CPC A61K 9/51 (2013.01) [A61K 9/127 (2013.01); A61K 9/1275 (2013.01); A61K 31/12 (2013.01); A61K 31/137 (2013.01); A61K 31/19 (2013.01); A61K 31/546 (2013.01); A61K 31/7034 (2013.01); A61K 31/713 (2013.01); A61K 38/14 (2013.01); A61K 38/28 (2013.01); A61K 39/29 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01)] 20 Claims
 
1. A method of treating a patient or subject in need of treatment of a disease state or condition comprising administering to said patient or subject a composition comprising one or more active molecules encapsulated in a liquid vesicle to provide an intact loaded vesicle wherein the outer surface coating of said loaded vesicle comprises at least one cholesteryl ester obtained from cholesterol and a C6-C26 fatty acid, said molecules obtaining in an effective amount an intracellular concentration in target cells of said patient or subject which is at least 2-fold greater than the concentration obtained by said molecules in the absence of said coating, wherein said molecules are selected from the group consisting of small molecules, proteins, monoclonal antibodies, peptides, polynucleotides, oligonucleotides, nucleic acids and mixtures thereof, wherein said administration includes at least one oral, parenteral or topical dosage form and said outer surface coating of said loaded vesicle remains intact during passage of said loaded vesicle across a membrane of a cell in said patient or subject and wherein said vesicle optionally releases said one or more molecules inside target cells by the action of cholesteryl ester hydrolases on said vesicle, and said disease state or condition is asthma, cancer, arthritis, Crohn's disease, multiple sclerosis, hyperlipidemia, obesity, type II diabetes, psoriasis, pulmonary arterial hypertension (PAH), inflammation, an intracellular viral, bacterial or fungal infection.